Puneet Gupta, MD
Neurology · Dallas, TXNPI 1942402466
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,970 of the $14,250 with a category attached, or 84.0%. Neurelis, Inc. accounts for 89.4% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2021 at $9,770 and has fallen 98.9% since, to $103 in 2025.
Across 69 payments — averaging $206.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurelis, Inc.$13K
- Immedica Pharma US, Inc.$172
- Neuropace, Inc.$158
- UCB, Inc.$155
- Lilly USA, LLC$149
- Omniscient Neurotechnology America Ltd$126
- plus $756 from 19 others
Across 4 payments — averaging $7846.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$31K
What the payments were for
- Speaking & faculty fees$11,97084%
- Travel & lodging$1591%
- Food & beverage$2,12215%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurelis, Inc. | 20 | $12,735 |
| Immedica Pharma US, Inc. | 1 | $172 |
| Neuropace, Inc. | 3 | $158 |
| UCB, Inc. | 5 | $155 |
| Lilly USA, LLC | 2 | $149 |
| Omniscient Neurotechnology America Ltd | 1 | $126 |
| Sunovion Pharmaceuticals Inc. | 8 | $115 |
| Pfizer | 6 | $108 |
| AbbVie(2 entities) | 4 | $81 |
| Monteris Medical Corporation | 2 | $67 |
| Zimmer Biomet | 1 | $57 |
| Ipsen Biopharmaceuticals, Inc | 2 | $41 |
| Biogen | 2 | $36 |
| Argenx US, Inc. | 1 | $34 |
| Microtransponder, Inc. | 1 | $32 |
| Eli Lilly | 1 | $24 |
| Livanova USA, Inc. | 1 | $22 |
| Adamas Pharmaceuticals, Inc. | 1 | $22 |
| Life Molecular Imaging Ltd | 1 | $20 |
| Aquestive Therapeutics, Inc. | 1 | $19 |
| Greenwich Biosciences, Inc. | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
| GE HealthCare | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Sanofi | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,250 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Dallas
- Nirav PavasiaDallas$1.4M
- Benjamin GreenbergDallas$773K
- Waleed El-FekyDallas$587K
- Adnan SubeiDallas$477K
- Steven HerzogDallas$461K
- Priyanka ChaudhryDallas$329K
- Deborah FriedmanDallas$284K
- Mark AlbertsDallas$212K
- Aanchal TanejaDallas$169K
- Salman BhaiDallas$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.